ethosuximide has been researched along with Anxiety in 9 studies
Ethosuximide: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
ethosuximide : A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures.
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chronic pain is a heavy burden disease." | 5.51 | Ethosuximide improves chronic pain-induced anxiety- and depression-like behaviors. ( Boudieu, L; Bourdier, J; Daulhac, L; Eschalier, A; Kerckhove, N; Mallet, C; Ourties, G, 2019) |
| "The anticonvulsant drug ethosuximide has shown diverse anxiety-related activity in rodents, but research in zebrafish is limited." | 3.85 | Behavioural responses of zebrafish larvae to acute ethosuximide exposure. ( Guo, N; Ji, Y; Li, F; Li, Q; Lin, J; Liu, X; Peng, X; Zhang, Y, 2017) |
| "Ethosuximide (ESX) is a drug of choice for the symptomatic treatment of absence seizures." | 3.79 | Ethosuximide reduces epileptogenesis and behavioral comorbidity in the GAERS model of genetic generalized epilepsy. ( Blumenfeld, H; Dezsi, G; Jones, NC; O'Brien, TJ; Ozturk, E; Powell, KL; Stanic, D, 2013) |
| "Chronic pain is a heavy burden disease." | 1.51 | Ethosuximide improves chronic pain-induced anxiety- and depression-like behaviors. ( Boudieu, L; Bourdier, J; Daulhac, L; Eschalier, A; Kerckhove, N; Mallet, C; Ourties, G, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Tomczuk, BE | 1 |
| Taylor, CR | 1 |
| Moses, LM | 1 |
| Sutherland, DB | 1 |
| Lo, YS | 1 |
| Johnson, DN | 1 |
| Kinnier, WB | 1 |
| Kilpatrick, BF | 1 |
| Kaur, S | 1 |
| Maslov, LN | 1 |
| Singh, N | 1 |
| Jaggi, AS | 1 |
| Kerckhove, N | 1 |
| Boudieu, L | 1 |
| Ourties, G | 1 |
| Bourdier, J | 1 |
| Daulhac, L | 1 |
| Eschalier, A | 1 |
| Mallet, C | 1 |
| Zhang, K | 1 |
| Jia, G | 1 |
| Xia, L | 1 |
| Du, J | 1 |
| Gai, G | 1 |
| Wang, Z | 1 |
| Cao, L | 1 |
| Zhang, F | 1 |
| Tao, R | 1 |
| Liu, H | 1 |
| Hashimoto, K | 1 |
| Wang, G | 1 |
| Cao, F | 1 |
| Liu, JJ | 1 |
| Zhou, S | 1 |
| Cortez, MA | 1 |
| Snead, OC | 1 |
| Han, J | 1 |
| Jia, Z | 1 |
| Ji, Y | 1 |
| Lin, J | 1 |
| Peng, X | 1 |
| Liu, X | 1 |
| Li, F | 1 |
| Zhang, Y | 1 |
| Guo, N | 1 |
| Li, Q | 1 |
| Dezsi, G | 1 |
| Ozturk, E | 1 |
| Stanic, D | 1 |
| Powell, KL | 1 |
| Blumenfeld, H | 1 |
| O'Brien, TJ | 1 |
| Jones, NC | 1 |
| Shaw, FZ | 1 |
| Chuang, SH | 1 |
| Shieh, KR | 1 |
| Wang, YJ | 1 |
| Bertoglio, LJ | 1 |
| Zangrossi, H | 1 |
1 review available for ethosuximide and Anxiety
| Article | Year |
|---|---|
Dual role of T-type calcium channels in anxiety-related behavior.
Topics: Animals; Anxiety; Calcium; Calcium Channels, T-Type; Ethosuximide | 2019 |
1 trial available for ethosuximide and Anxiety
| Article | Year |
|---|---|
Efficacy of anticonvulsant ethosuximide for major depressive disorder: a randomized, placebo-control clinical trial.
Topics: Adult; Anticonvulsants; Anxiety; Depressive Disorder, Major; Double-Blind Method; Ethosuximide; Fema | 2021 |
7 other studies available for ethosuximide and Anxiety
| Article | Year |
|---|---|
2-Phenyl-3H-imidazo[4,5-b]pyridine-3-acetamides as non-benzodiazepine anticonvulsants and anxiolytics.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Anxiety; Benzodiazepines; Binding, Competitive; Cereb | 1991 |
Ethosuximide improves chronic pain-induced anxiety- and depression-like behaviors.
Topics: Animals; Anticonvulsants; Anxiety; Calcium Channel Blockers; Calcium Channels, T-Type; Chronic Pain; | 2019 |
Neuroligin 2 regulates absence seizures and behavioral arrests through GABAergic transmission within the thalamocortical circuitry.
Topics: Action Potentials; Animals; Anxiety; Behavior, Animal; Cell Adhesion Molecules, Neuronal; Electrodes | 2020 |
Behavioural responses of zebrafish larvae to acute ethosuximide exposure.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Anxiety; Behavior, Animal; Darkness; Ethosuximide; La | 2017 |
Ethosuximide reduces epileptogenesis and behavioral comorbidity in the GAERS model of genetic generalized epilepsy.
Topics: Aging; Animals; Anticonvulsants; Anxiety; Behavior, Animal; Body Weight; Brain; DNA (Cytosine-5-)-Me | 2013 |
Depression- and anxiety-like behaviors of a rat model with absence epileptic discharges.
Topics: Action Potentials; Animals; Anticonvulsants; Anxiety; Depression; Disease Models, Animal; Epilepsy, | 2009 |
Involvement of dorsolateral periaqueductal gray N-methyl-D-aspartic acid glutamate receptors in the regulation of risk assessment and inhibitory avoidance behaviors in the rat elevated T-maze.
Topics: 2-Amino-5-phosphonovalerate; Animals; Anticonvulsants; Anxiety; Ethosuximide; Excitatory Amino Acid | 2006 |